Growing concerns over semaglutide weight loss drugs as patents set to expire Growing concerns over semaglutide weight loss drugs as patents set to expire As demand surges for weight loss drugs, Kamil Karamali looks at rising safety concerns and potential side effects
Or maybe I need to take it a bit longer
Link to full post: GLP-1 Drugs, Digital Health & Obesity Trends in 2026 Overweight and obesity are driving a booming digital health market through telehealth, wearables, and new pharma-to-consumer models
Studies indicate that individuals with pancreatic risk factors or a history of pancreatic disease may need to exercise additional caution when using GLP-1 and GIP receptor agonists
Additionally, the superiority of GLP-1RAs compared to placebo in the primary endpoint of 3-MACE were found with liraglutide in the LEADER trial (HR 0.87
For various reasons, bacteria from the large intestine can enter the small intestine and cause small intestinal bacterial overgrowth (SIBO)